Deal notes
This is an ATM facility event. The capacity shown is not cash raised.
Transaction overview
01OS Therapies Inc disclosed an at-the-market program event: facility established. Authorized capacity is $75.0M. This event does not record cash proceeds raised.
- Financing type
- ATM
- Announcement date
- —
- SEC disclosure date
- Aug 21, 2026
- Agreement date
- Aug 21, 2026
- Pricing date
- —
- Closing date
- —
- Filing date
- Aug 21, 2026
- Status
- Announced
- Market cap before SEC disclosure
- $69.4M
- Prior closing price
- $1.58
- Raise as % of market cap
- —
Market data · FMP
- Historical market cap
- $69,368,571
- Market date
- Aug 20, 2026
- Closing price
- $1.58
- Latest reported shares outstanding
- 45,538,100
- Latest reported float shares
- 25,970,036
- Share-data date
- Oct 2, 2026
Market cap and closing price are from FMP for the date shown. Shares are FMP’s latest available snapshot, dated separately. Updated Oct 2, 2026.
Financial Modeling Prep ↗Financing terms
02At-the-market program
- Capital event
- Facility established
- Authorized capacity
- $75.0M
- Proceeds raised
- Not reported as raised
- Shares sold
- —
- Average sale price
- —
- Relevant period
- Not applicable
- Sales commission
- 3%
Fees & transaction economics
03- Placement agent / underwriting fee
- 3%
- Agent fee amount
- —
- Management fee
- —
- Other offering expenses (estimated)
- —
- Net proceeds (estimated)
- —
- Net proceeds as % of gross
- —
Fee amounts reflect disclosed inputs. Unknown expense components are not assumed to be zero.
3% sales commission; counsel reimbursement capped at $100,000 at execution plus specified ongoing disbursements. Total offering expenses estimated at $350,000 excluding commissions and Jefferies expense reimbursement; actual costs and proceeds are unknown.
Transaction participants
04Source documents
05SEC filings, exhibits and attributed market data. The report separates disclosed facts, calculated metrics, and unknown terms.
Filing evidence & original calculations
75000000
On August 21, 2026, OS Therapies Incorporated (the “Company”) entered into an Open Market Sale Agreement℠ (the “Sales Agreement”) with Jefferies LLC (the “Sales Agent”), pursuant to which the Company may offer and sell shares of its common stock from time to time through or to the Sales Agent in connection with the Company’s “at the market offering” program (the “ATM Offering”). On August 21, 2026, the Company filed with the Securities and Exchange Commission (the “SEC”) a prospectus supplement (the “Prospectus Supplement”) relating to the ATM Offering under the Company’s shelf registration statement on Form S-3 (File No. 333-289443) filed by the Company with the SEC on August 8, 2025 and declared effective by the SEC on August 25, 2025 (the “Registration Statement”). Pursuant to the Prospectus Supplement, the Company may offer and sell shares of its common stock having an aggregate offering price of up to $75 million pursuant to the Sales Agreement (the “Shares”).Original source ↗
ATM
On August 21, 2026, OS Therapies Incorporated (the “Company”) entered into an Open Market Sale Agreement℠ (the “Sales Agreement”) with Jefferies LLC (the “Sales Agent”), pursuant to which the Company may offer and sell shares of its common stock from time to time through or to the Sales Agent in connection with the Company’s “at the market offering” program (the “ATM Offering”). On August 21, 2026, the Company filed with the Securities and Exchange Commission (the “SEC”) a prospectus supplement (the “Prospectus Supplement”) relating to the ATM Offering under the Company’s shelf registration statement on Form S-3 (File No. 333-289443) filed by the Company with the SEC on August 8, 2025 and declared effective by the SEC on August 25, 2025 (the “Registration Statement”). Pursuant to the Prospectus Supplement, the Company may offer and sell shares of its common stock having an aggregate offering price of up to $75 million pursuant to the Sales Agreement (the “Shares”).Original source ↗
2026-08-21
On August 21, 2026, OS Therapies Incorporated (the “Company”) entered into an Open Market Sale Agreement℠ (the “Sales Agreement”) with Jefferies LLC (the “Sales Agent”), pursuant to which the Company may offer and sell shares of its common stock from time to time through or to the Sales Agent in connection with the Company’s “at the market offering” program (the “ATM Offering”). On August 21, 2026, the Company filed with the Securities and Exchange Commission (the “SEC”) a prospectus supplement (the “Prospectus Supplement”) relating to the ATM Offering under the Company’s shelf registration statement on Form S-3 (File No. 333-289443) filed by the Company with the SEC on August 8, 2025 and declared effective by the SEC on August 25, 2025 (the “Registration Statement”). Pursuant to the Prospectus Supplement, the Company may offer and sell shares of its common stock having an aggregate offering price of up to $75 million pursuant to the Sales Agreement (the “Shares”).Original source ↗
3
The Company will pay the Sales Agent a commission equal to 3.0% of the aggregate gross proceeds the Company receives from each sale of Shares pursuant to the Sales Agreement.Original source ↗
sec_disclosure
On August 21, 2026, OS Therapies Incorporated (the “Company”) entered into an Open Market Sale Agreement℠ (the “Sales Agreement”) with Jefferies LLC (the “Sales Agent”), pursuant to which the Company may offer and sell shares of its common stock from time to time through or to the Sales Agent in connection with the Company’s “at the market offering” program (the “ATM Offering”). On August 21, 2026, the Company filed with the Securities and Exchange Commission (the “SEC”) a prospectus supplement (the “Prospectus Supplement”) relating to the ATM Offering under the Company’s shelf registration statement on Form S-3 (File No. 333-289443) filed by the Company with the SEC on August 8, 2025 and declared effective by the SEC on August 25, 2025 (the “Registration Statement”). Pursuant to the Prospectus Supplement, the Company may offer and sell shares of its common stock having an aggregate offering price of up to $75 million pursuant to the Sales Agreement (the “Shares”).Original source ↗
2026-08-21
On August 21, 2026, OS Therapies Incorporated (the “Company”) entered into an Open Market Sale Agreement℠ (the “Sales Agreement”) with Jefferies LLC (the “Sales Agent”), pursuant to which the Company may offer and sell shares of its common stock from time to time through or to the Sales Agent in connection with the Company’s “at the market offering” program (the “ATM Offering”). On August 21, 2026, the Company filed with the Securities and Exchange Commission (the “SEC”) a prospectus supplement (the “Prospectus Supplement”) relating to the ATM Offering under the Company’s shelf registration statement on Form S-3 (File No. 333-289443) filed by the Company with the SEC on August 8, 2025 and declared effective by the SEC on August 25, 2025 (the “Registration Statement”). Pursuant to the Prospectus Supplement, the Company may offer and sell shares of its common stock having an aggregate offering price of up to $75 million pursuant to the Sales Agreement (the “Shares”).Original source ↗
Announced
On August 21, 2026, OS Therapies Incorporated (the “Company”) entered into an Open Market Sale Agreement℠ (the “Sales Agreement”) with Jefferies LLC (the “Sales Agent”), pursuant to which the Company may offer and sell shares of its common stock from time to time through or to the Sales Agent in connection with the Company’s “at the market offering” program (the “ATM Offering”). On August 21, 2026, the Company filed with the Securities and Exchange Commission (the “SEC”) a prospectus supplement (the “Prospectus Supplement”) relating to the ATM Offering under the Company’s shelf registration statement on Form S-3 (File No. 333-289443) filed by the Company with the SEC on August 8, 2025 and declared effective by the SEC on August 25, 2025 (the “Registration Statement”). Pursuant to the Prospectus Supplement, the Company may offer and sell shares of its common stock having an aggregate offering price of up to $75 million pursuant to the Sales Agreement (the “Shares”).Original source ↗
Facility established
On August 21, 2026, OS Therapies Incorporated (the “Company”) entered into an Open Market Sale Agreement℠ (the “Sales Agreement”) with Jefferies LLC (the “Sales Agent”), pursuant to which the Company may offer and sell shares of its common stock from time to time through or to the Sales Agent in connection with the Company’s “at the market offering” program (the “ATM Offering”). On August 21, 2026, the Company filed with the Securities and Exchange Commission (the “SEC”) a prospectus supplement (the “Prospectus Supplement”) relating to the ATM Offering under the Company’s shelf registration statement on Form S-3 (File No. 333-289443) filed by the Company with the SEC on August 8, 2025 and declared effective by the SEC on August 25, 2025 (the “Registration Statement”). Pursuant to the Prospectus Supplement, the Company may offer and sell shares of its common stock having an aggregate offering price of up to $75 million pursuant to the Sales Agreement (the “Shares”).Original source ↗
Authorized capacity
On August 21, 2026, OS Therapies Incorporated (the “Company”) entered into an Open Market Sale Agreement℠ (the “Sales Agreement”) with Jefferies LLC (the “Sales Agent”), pursuant to which the Company may offer and sell shares of its common stock from time to time through or to the Sales Agent in connection with the Company’s “at the market offering” program (the “ATM Offering”). On August 21, 2026, the Company filed with the Securities and Exchange Commission (the “SEC”) a prospectus supplement (the “Prospectus Supplement”) relating to the ATM Offering under the Company’s shelf registration statement on Form S-3 (File No. 333-289443) filed by the Company with the SEC on August 8, 2025 and declared effective by the SEC on August 25, 2025 (the “Registration Statement”). Pursuant to the Prospectus Supplement, the Company may offer and sell shares of its common stock having an aggregate offering price of up to $75 million pursuant to the Sales Agreement (the “Shares”).Original source ↗
3% sales commission; counsel reimbursement capped at $100,000 at execution plus specified ongoing disbursements. Total offering expenses estimated at $350,000 excluding commissions and Jefferies expense reimbursement; actual costs and proceeds are unknown.
In addition, we have agreed to reimburse Jefferies for the fees and disbursements of its counsel, payable upon execution of the Sales Agreement, in an amount not to exceed $100,000, in addition to certain ongoing disbursements of its legal counsel. We estimate that the total expenses for the offering, excluding any commissions or expense reimbursement payable to Jefferies under the terms of the Sales Agreement, will be approximately $350,000. The remaining sale proceeds, after deducting any other transaction fees, will equal our net proceeds from the sale of such shares.Original source ↗
FMP reported market cap; as of 2026-08-20.
{"provider": "FMP", "symbol": "OSTX", "date": "2026-08-20", "marketCap": 69368571}Original source ↗